Precigen's (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism [Yahoo! Finance]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
proprietary therapeutic platforms, its UltraCAR-T platform offers a differentiated approach to CAR-T treatment, aiming for faster manufacturing and potentially improved safety profiles. The company has multiple candidates progressing through clinical trials, which are being used to build a robust pipeline that addresses significant unmet medical needs. Precigen's (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism Precigen Inc.'s (NASDAQ:PGEN) stock is up over 300% year-to-date. Its share price has doubled since mid-August after the successful FDA approval of its Papzimeos therapy, which is the first and only approved treatment for adults with recurrent respiratory papillomatosis. The approval was seen as highly favourable by the street. Following the news, analysts from JPMorgan had upgraded the stock to Neutral from Underweight, citing the removal of a major overhang. Analysts from Cantor Fitzgerald and H.C. Wainwright had also reiterated their Buy rat
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]Seeking Alpha
- Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]Seeking Alpha
- Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]Yahoo! Finance
- Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 [Yahoo! Finance]Yahoo! Finance
PGEN
Earnings
- 11/13/25 - Miss
PGEN
Sec Filings
- 11/21/25 - Form SCHEDULE
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- PGEN's page on the SEC website